in the absence of a submission from the holder of the marketing authorisation:
satralizumab (Enspryng®) is not recommended for use within NHSScotland.
Indication under review: As a monotherapy or in combination with immunosuppressive therapy (IST) for the treatment of neuromyelitis optica spectrum disorders (NMOSD) in adult and adolescent patients from 12 years of age who are anti-aquaporin-4 IgG (AQP4-IgG) seropositive.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice240KB (PDF)
Medicine details
- Medicine name:
- satralizumab (Enspryng)
- SMC ID:
- SMC2663
- Indication:
As a monotherapy or in combination with immunosuppressive therapy (IST) for the treatment of neuromyelitis optica spectrum disorders (NMOSD) in adult and adolescent patients from 12 years of age who are anti-aquaporin-4 IgG (AQP4-IgG) seropositive.
- Pharmaceutical company
- Roche
- BNF chapter
- Central nervous system
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 11 March 2024